pentobarbital will reduce the level or outcome of conjugated estrogens by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
pentobarbital will reduce the level or result of lonafarnib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib is really a sensitive CYP3A4 substrate. Coadministration with sturdy or reasonable CYP3A4 inducers is contraindicated.
pentobarbital will lessen the extent or outcome of acalabrutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
pentobarbital will lessen the level or result of losartan by influencing hepatic enzyme CYP2C9/10 metabolism. Insignificant/Significance Mysterious.
pentobarbital will decrease the extent or effect of estradiol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
pentobarbital will decrease the extent or result of ethinylestradiol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Prevent or Use Alternate Drug. The efficacy of hormonal contraceptives could possibly be diminished. Use of a nonhormonal contraceptive is usually recommended.
pentobarbital will lessen the extent or effect of sufentanil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Unidentified.
pentobarbital will decrease the extent or more info outcome of cilostazol by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
To minimize the opportunity of overdosage or the event of dependence, Restrict the prescribing and dispensing of sedative-hypnotic barbiturates, to the quantity essential for your interval until another appointment
pentobarbital will lower the extent or result of fentanyl transmucosal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Closely. Coadministration of fentanyl with CYP3A4 inducers could lead on to some minimize in fentanyl plasma concentrations, insufficient efficacy or, possibly, progress of a withdrawal syndrome in a client who has formulated physical dependence to fentanyl.
pentobarbital will minimize the extent or impact of cobimetinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Steer clear of coadministration. Robust or reasonable CYP3A inducers may perhaps decrease cobimetinib systemic exposure by >80% and decrease its efficacy.
pentobarbital will decrease the level or influence of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.
pentobarbital will decrease the extent or outcome of dienogest/estradiol valerate by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Gals must not pick out estradiol valerate/dienogest as their contraceptive while using strong CYP3A4 inducers because of possible reduce in contraceptive efficacy.
pentobarbital will reduce the extent or influence of vinorelbine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Unidentified.